SCHEMBL351424

SCHEMBL351424

NC(=O)C(C(=O)O)c1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 4/20 0.49
CYP2C19 P33261 3/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
CYP2D6 P10635 2/20 0.49
SRC P12931 1/20 0.48
GABBR2 O75899 3/20 0.47
GABBR1 Q9UBS5 3/20 0.47
LMNA P02545 2/20 0.47
TSHR P16473 2/20 0.47
CYP3A4 P08684 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
NFKB1 P19838 1/20 0.47
DRD3 P35462 1/20 0.47
BLM P54132 1/20 0.47
CYP1A2 P05177 1/20 0.47
THRB P10828 1/20 0.47
BRD4 O60885 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29386802 0.89 BRD4 (0.48) CYP2C9CYP2C19MEN1KMT2ACYP2D6
SCHEMBL5220963 0.89 SRC (0.61) CYP2C9CYP2C19MEN1KMT2ACYP2D6
SCHEMBL11217394 0.83 SRC (0.48) CYP2C9CYP2D6SRCLMNAPOLB
SCHEMBL11215807 0.81 SRC (0.46) CYP2C9CYP2C19MEN1KMT2ACYP2D6
SCHEMBL22265095 0.81 BRD4 (0.57) CYP2C9CYP2C19MEN1KMT2ACYP2D6
SCHEMBL9427838 0.81 SRC (0.46) CYP2C9CYP2C19MEN1KMT2ACYP2D6
SCHEMBL38660598 0.81 BRD4 (0.57) CYP2C9CYP2C19MEN1KMT2ACYP2D6
SCHEMBL4385009 0.80 HDAC4 (0.47) CYP2C9CYP2C19MEN1KMT2ACYP2D6
SCHEMBL8126795 0.80 SRC (0.50) KMT2ASRCTSHRNFKB1ALOX15
SCHEMBL1581315 0.79 SRC (0.76) CYP2C19CYP2D6SRCLMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120015976-A1 AUTOTAXIN INHIBITORS MERCK PATENT GESELLSCHAFT MIT BESCHRANK TER HAFTUNG (DE) 2012-01-19 US disclosed
US-8048890-B2 Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents GRUENENTHAL GMBH (DE) 2011-11-01 US disclosed
US-8048879-B2 Substituted 4,5,6,7-tetrahydro-isoxazolo[4,5-c]pyridine compounds and use thereof for producing medicaments GRUENENTHAL GMBH (DE) 2011-11-01 US disclosed
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods GRUENENTHAL GMBH (DE) 2011-09-15 US disclosed
US-4329454-A Cephalosporin compounds ELI LILLY AND COMPANY (US) 1982-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods SULT1E1, DECR1, CYP8B1 CYP2C9 50/4885CYP2C19 77/4885MEN1 2995/4885
US-20120015976-A1 AUTOTAXIN INHIBITORS ENPP2, PLA2G12A, LPCAT1 CYP2C9 4824/4885CYP2C19 4710/4885MEN1 186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.